The United States cardiac resynchronization therapy market witnessed significant growth in the past and is expected to grow at a CAGR of 6.2% during the forecast period (2022-2030).
Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.
The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.
-market.jpg)
Nearly half of all deaths from cardiovascular diseases are caused by sudden cardiac death, which continues to be a primary cause of mortality despite advancements in prevention and treatment. Devices for cardiac resynchronization therapy should see increased demand due to the rising prevalence of heart diseases and their risk factors. One of the top causes of death worldwide is heart failure. As of September 2020, the CDC estimates that 6.2 million persons with Heart failure plagued the U.S. A total of 379,800 death certificates, or roughly 13.4% of all death certificates, listed it as a cause of death in 2018.
As a result, it is projected that the rising prevalence of cardiovascular disorders would increase demand for a range of therapeutic options, including cardiac resynchronization therapy devices.
Implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT-Ds), the Viva, Evera, Brava, Amplia, Claria, Visia, and Compia devices, as well as their distribution between August 31, 2012, and May 9, 2018, were all recalled by Medtronic in February 2021. An unexpected and abrupt decline in battery life led to the recall.
Boston Scientific Corporation started the INGENIO family of pacemakers and CRT-Ps recall in June 2021. ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL are a few of them. Between November 2011 and August 2020, devices that have been recalled were distributed and manufactured between September 2011 and December 2018. In the U.S., some 48,000 gadgets were recalled. The possibility of the gadget entering safety mode led to the recall.
In older people, heart failure is a prevalent condition. In the U.S., an estimated 5.7 million people suffer from heart failure. The disease known as heart failure occurs when the heart cannot pump enough blood to meet the body's demands. This may result from numerous symptoms, including weariness, edema, and shortness of breath.
Heart failure is treated using CRT therapy, which synchronizes the electrical activity of the heart’s lower chambers using a pacemaker and one or two leads. This can enhance the heart's capacity to pump blood and lessen heart failure signs and symptoms.
| Study Period | 2020-2032 | CAGR | 6.2% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD XX Billion |
| Forecast Year | 2032 | Forecast Year Market Size | USD XX Billion |
The U.S. cardiac resynchronization therapy market is anticipated to develop faster than average because of the rising death rate from cardiac illnesses. For instance, as of September 2021, the CDC estimates that 1 in every four fatalities in the U.S. was caused by heart disease. In addition, one of the main killers in the nation is heart disease. As a result, the market is projected to rise due to the large increase in demand for CRT to reduce mortality from cardiac diseases. Due to supportive government programs to enhance cardiovascular health, the U.S. CRT market is predicted to have significant growth. For instance, the National Health and Nutrition Examination Survey gathers information from the U.S. population to evaluate the prevalence of CVDs and their risk factors, including cigarette use, poor food choices, inactivity, and biometric measurements (DNA repositories & biospecimen). The information can assist the government in allocating private and public resources for CVD prevention and treatment. The country's CRT market is anticipated to increase due to these measures.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The United States cardiac resynchronization therapy (CRT) market is segmented based on Product, End-User, and Country.
Based on OS, the United States market is segmented by CRT-D and CRT-P.
CRT-D dominated the market over the forecast period.
Based on End-User, the United States market is segmented by Hospitals, Cardiac Centre.
Hospitals dominated the market over the forecast period.
